ATE254095T1 - Selektive analoge der thyroidhormone - Google Patents

Selektive analoge der thyroidhormone

Info

Publication number
ATE254095T1
ATE254095T1 AT98926384T AT98926384T ATE254095T1 AT E254095 T1 ATE254095 T1 AT E254095T1 AT 98926384 T AT98926384 T AT 98926384T AT 98926384 T AT98926384 T AT 98926384T AT E254095 T1 ATE254095 T1 AT E254095T1
Authority
AT
Austria
Prior art keywords
thyroid hormones
selective
selective analogue
disclosed
analogue
Prior art date
Application number
AT98926384T
Other languages
German (de)
English (en)
Inventor
Thomas S Scanlan
Grazia Chellini
Hikari Yoshihara
James Apriletti
John D Baxter
Ralff Ribeiro
Ave Rm Hsw Parnassus
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE254095T1 publication Critical patent/ATE254095T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT98926384T 1997-06-18 1998-06-08 Selektive analoge der thyroidhormone ATE254095T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/877,792 US5883294A (en) 1997-06-18 1997-06-18 Selective thyroid hormone analogs
PCT/US1998/011758 WO1998057919A1 (en) 1997-06-18 1998-06-08 Selective thyroid hormone analogs

Publications (1)

Publication Number Publication Date
ATE254095T1 true ATE254095T1 (de) 2003-11-15

Family

ID=25370738

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98926384T ATE254095T1 (de) 1997-06-18 1998-06-08 Selektive analoge der thyroidhormone

Country Status (9)

Country Link
US (1) US5883294A (enExample)
EP (1) EP0991618B1 (enExample)
JP (1) JP2002511084A (enExample)
KR (1) KR20010013999A (enExample)
AT (1) ATE254095T1 (enExample)
AU (1) AU746991B2 (enExample)
CA (1) CA2290622C (enExample)
DE (1) DE69819726T2 (enExample)
WO (1) WO1998057919A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0873361B1 (en) 1995-12-13 2006-11-02 The Regents Of The University Of California Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6217598B1 (en) * 1997-11-25 2001-04-17 Linvatec Corporation End-cutting shaver blade
EP1598334A1 (en) * 1998-06-30 2005-11-23 The Regents Of The University Of California Thyroid hormone analogues and methods for their preparation
AR018699A1 (es) 1999-06-01 2001-11-28 Procter & Gamble Metodo para el tratamiento de la perdida del cabello el cual comprende administrar una composicion que comprende un compuesto el cual no afecta al corazon
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
CA2374263A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylether derivatives
WO2000072813A1 (en) * 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
US6516294B1 (en) 1999-07-01 2003-02-04 The Regents Of The University Of California Nuclear receptor for 1α,25-dihydroxyvitamin D3 useful for selection of vitamin D3 ligands and a method therefor
DE10024939A1 (de) 2000-05-19 2001-11-29 Bayer Ag Neue Diphenylmethanderivate für Arzneimittel
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
CA2433100A1 (en) 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
US6716877B2 (en) 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels
US6534676B2 (en) 2001-01-31 2003-03-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
US7504435B2 (en) 2001-01-31 2009-03-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for stimulating weight loss and/or for lowering triglycerides in patients
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
US20040253648A1 (en) * 2002-12-10 2004-12-16 The Regents Of The University Of California Method for creating nuclear receptor activity modulating pharmaceuticals
US7302347B2 (en) * 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
CA2546601A1 (en) * 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2005085865A2 (en) * 2004-03-09 2005-09-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb)
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
US20060292194A1 (en) * 2005-06-24 2006-12-28 Thomas Lavin Treatment for burns and adipose deposits using thyroid hormone compound in a human
KR100965006B1 (ko) 2005-07-21 2010-06-21 에프. 호프만-라 로슈 아게 갑상선 호르몬 수용체 작용제로서 피리다진온 유도체
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
AU2008219585A1 (en) * 2007-02-27 2008-09-04 The Arizona Board Of Regents On Behalf Of The University Of Arizona Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome.
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
WO2009089093A1 (en) * 2008-01-04 2009-07-16 Quatrx Pharmaceuticals Company Thyroid hormone receptor agonists
JP2016517883A (ja) 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
JP2018510849A (ja) * 2015-02-20 2018-04-19 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ ソベチロムの誘導体
US11872207B2 (en) 2015-12-24 2024-01-16 Mcmaster University Dronedarone and derivatives thereof for treating cancer
CA3008041C (en) 2015-12-24 2024-02-13 Mcmaster University Compounds for treating cancer
KR102331596B1 (ko) 2016-05-18 2021-11-25 오레곤 헬스 앤드 사이언스 유니버시티 소베티롬의 유도체
US11325886B2 (en) 2016-08-12 2022-05-10 Oregon Health & Science University Amide compounds, pharmaceutical compositions thereof, and methods of using the same
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11660281B2 (en) * 2017-06-29 2023-05-30 Yale University Compositions and methods of treating or preventing fibrotic lung diseases
WO2019160980A1 (en) 2018-02-14 2019-08-22 Oregon Health & Science University Derivatives of sobetirome
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CA3122996A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
EP3931180A1 (en) 2019-03-01 2022-01-05 Autobahn Therapeutics, Inc. Novel thyromimetics
IT201900006923A1 (it) * 2019-05-16 2020-11-16 International Soc For Drug Development S R L Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso
KR20220121239A (ko) 2019-11-29 2022-08-31 아우토반 쎄라퓨틱스, 인크. 신규한 갑상선 호르몬 모방제
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物
JP2023530708A (ja) * 2020-06-17 2023-07-19 オートバーン セラピューティクス，インク． 甲状腺様作用剤
US20230242473A1 (en) * 2020-06-17 2023-08-03 Autobahn Therapeutics, Inc. Thyromimetics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323691A (en) * 1979-10-09 1982-04-06 Abbott Laboratories Hydroxyaminomethyl derivatives of benzoyl di-substituted α-phenoxyalkanoyl esters
CA1149803A (en) * 1979-10-09 1983-07-12 Carroll W. Ours HYDROXYAMINOMETHYL DERIVATIVES OF BENZOYL DI-SUBSTITUTED .alpha.-PHENOXY ALKANOYL ESTERS
IT1218855B (it) * 1984-12-28 1990-04-24 Ates Componenti Elettron Stadio amplificatore di segnali, integrato monoliticamente, ad alta dinamica di uscita
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
JPH05170690A (ja) * 1991-12-20 1993-07-09 Mitsui Toatsu Chem Inc ジフェニル炭化水素誘導体を有効成分として含有する血栓溶解促進剤
DE4327365A1 (de) * 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
EP1598334A1 (en) * 1998-06-30 2005-11-23 The Regents Of The University Of California Thyroid hormone analogues and methods for their preparation

Also Published As

Publication number Publication date
KR20010013999A (ko) 2001-02-26
DE69819726T2 (de) 2004-09-30
EP0991618A1 (en) 2000-04-12
CA2290622C (en) 2008-08-05
JP2002511084A (ja) 2002-04-09
CA2290622A1 (en) 1998-12-23
WO1998057919A1 (en) 1998-12-23
EP0991618A4 (en) 2000-09-27
AU7823498A (en) 1999-01-04
US5883294A (en) 1999-03-16
DE69819726D1 (de) 2003-12-18
AU746991B2 (en) 2002-05-09
EP0991618B1 (en) 2003-11-12

Similar Documents

Publication Publication Date Title
ATE254095T1 (de) Selektive analoge der thyroidhormone
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
EE02962B1 (et) Mometasoonfuroaadi monohüdraat, selle valmistamismeetod ja farmatseutilised kompositsioonid
IL56581A (en) 6-substituted-8-(methoxymethyl)or(methylmercaptomethyl)ergolines and ergolenes,their preparation and pharmaceutical compositions containing them
PL361707A1 (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
NZ512792A (en) Stable liquid interferon beta formulations
TWI263640B (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
JO2034B1 (en) Isotopes of the hormone peptide its uses and the chemical compounds it contains
FI903440A7 (fi) Stabiloidut FGF-koostumukset ja menetelmä niiden valmistamiseksi
AU2002364082A1 (en) Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
NO20003534L (no) Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
AU2002359727A1 (en) Fused cyclic modulators of nuclear hormone receptor function
IL140140A0 (en) Thyroid hormone analogues and methods for their preparation
BR0111869A (pt) Compostos cìclicos fundidos como moduladores da função do receptor para homÈnio nuclear
FI843560A7 (fi) Mevalonolaktonin analogeja ja niiden johdannaisia, menetelmiä niiden valmistamiseksi, niitä sisältäviä farmaseuttisia yhdistelmiä ja niide n käyttö farmaseuttisina aineina.
MX24890A (es) Polipeptido sintetico, procedimiento par su preparacion y composicion farmaceutica que lo contiene.
IT8348155A0 (it) Benzoazacicloalchilspiro-imidazolidine,procedimento per prepararle e composizioni farmaceutiche che le contengono
IT8026672A0 (it) Derivati peptidici, procedimento per prepararli e relative composizioni farmaceutiche.
MD970269A (en) Clavulanates
BG102229A (en) Endothelium receptor antagonists
NO985079L (no) Eksplosiv formulering
ATE122895T1 (de) Monoklonale antikörper gegen den interleukin 2- rezeptor.
TR199901054T2 (xx) Bi�imsel olarak k�s�tlanm�� LH-RH analoglar�, bunlar�n kullan�mlar� ve bunlar� i�eren farmas�tik terkipler.
EP0778833A4 (en) ENDOTHELIN RECEPTOR ANTAGONISTS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties